REGN
Regeneron Pharmaceuticals Inc
798.20$
+1.7%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +76.9% | +11.7% | -12.0% | +67.9% | +10.7% | +7.7% | +170.5% | -29.2% | -8.4% | -3.8% | +12.6% | |
| – | +42.2% | +39.8% | +38.9% | +1.9% | +41.9% | +12.2% | +21.3% | +19.3% | +23.3% | +14.7% | +12.6% | |
| – | +49.4% | +22.0% | -9.4% | -15.7% | +8.6% | -7.0% | +39.3% | +20.5% | +22.1% | +11.1% | +1.1% | |
| – | +75.8% | -16.8% | -81.2% | -329.6% | – | -384.9% | – | – | – | – | – | |
| – | +1,035.6% | -0.7% | -506.0% | – | – | – | – | – | – | – | – | |
| – | +103.6% | -24.5% | -46.7% | +40.5% | +12.1% | +43.1% | -10.2% | +6.9% | +57.0% | -18.4% | +18.9% | |
| – | +115.7% | +15.3% | -4.0% | +45.5% | +38.6% | -96.5% | +7,527.1% | -29.7% | -15.8% | -22.5% | -74.5% | |
| – | +85.9% | -8.6% | -28.3% | – | – | – | – | – | – | – | – | |
| – | -40.0% | -10.8% | +110.7% | -36.5% | +142.1% | +1,307.1% | -59.0% | -5.6% | -11.6% | +62.5% | +9.3% | |
| – | -36.7% | -71.1% | – | +5,245.7% | +0.0% | +0.0% | -100.0% | – | – | – | – | |
| – | +20.2% | +166.5% | -96.5% | +216.0% | +227.0% | +681.6% | -49.0% | +0.3% | +77.4% | +22.9% | +68.8% | |
| – | +41.8% | -270.8% | – | +136.0% | -77.1% | +284.4% | +19.7% | -68.0% | -272.4% | – | – | |
| – | +55.7% | +49.2% | +6.2% | +75.2% | +10.4% | +0.2% | +225.9% | -32.2% | -17.1% | -0.1% | +11.3% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.